Physician profile
Lynnette Brown
NPI 1508010539
$1,763.45
in general payments reported to CMS, 2019-2025
20 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $210 · 2024: $902 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.82 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $173.65 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $152.36 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $144.34 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $139.12 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Abbvie INC. | $104.83 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $103.01 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $96.42 | 2023-2025 | Shingrix, Arexvy, Penmenvy |
| Pfizer INC. | $73.48 | 2023-2025 | |
| Astellas Pharma US INC | $49.48 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $47.68 | 2024 | Xarelto |
| Lilly USA, LLC | $45.16 | 2024 | Jardiance, Mounjaro, Zepbound |
| Phadia US INC. | $31.34 | 2023-2024 | Immunocap |
| Neurelis, INC. | $28.94 | 2024 | Valtoco |
| Bayer Healthcare Pharmaceuticals INC. | $25.32 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $23.85 | 2024 | Nayzilam |
| Corium, LLC | $23.20 | 2023 | Azstarys |
| Cequr Corporation | $20.21 | 2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $18.38 | 2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynnette Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.